Study: NCT02532998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 oral suspension
Description: AZD9977 oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 oral suspension
Description: AZD9977 oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 oral suspension
Description: AZD9977 oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 oral suspension
Description: AZD9977 oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 oral suspension
Description: AZD9977 oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 oral suspension
Description: AZD9977 oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 oral suspension
Description: AZD9977 oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 oral suspension
Description: AZD9977 oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 placebo oral suspension
Description: oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 placebo oral suspension
Description: oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 placebo oral suspension
Description: oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 placebo oral suspension
Description: oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 placebo oral suspension
Description: oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 placebo oral suspension
Description: oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 placebo oral suspension
Description: oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 placebo oral suspension
Description: oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone, tablets
Description: Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone, tablets
Description: Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone, tablets
Description: Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone, tablets
Description: Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone, tablets
Description: Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone, tablets
Description: Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone, tablets
Description: Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone, tablets
Description: Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone, tablets
Description: 100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone, tablets
Description: 100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone, tablets
Description: 100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone, tablets
Description: 100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone, tablets
Description: 100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone, tablets
Description: 100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone, tablets
Description: 100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone, tablets
Description: 100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)